Chronic myelogenous leukemia, version 1.2015

Susan O'Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu V.B. Reddy, Neil P. Shah, B. Douglas Smith, David S. SnyderMeir Wetzler, Kristina Gregory, Hema Sundar

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

Original languageEnglish (US)
Pages (from-to)1590-1610
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number11
StatePublished - Nov 1 2014

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Chronic myelogenous leukemia, version 1.2015'. Together they form a unique fingerprint.

Cite this